CoChat

NRF2 and p53: Januses in cancer?

Open access
Rotblat, Barak, Melino, Gerry, Knight, Richard A. · 2012 · Oncotarget
Cited by 109

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

// Barak Rotblat 1 , Gerry Melino 1,2 , Richard A. Knight 1 1 Medical research Council, Toxicology Unit, Leicester University, Leicester, UK 2 Biochemistry IDI-IRCCS Laboratory, Department of Experimental Medicine and Surgery, University of Rom ‘Tor Vergata’, Rome, Italy Correspondence: Gerry Melino, email: // Keywords : P53, p73, TIGAR, p21, NQO1, NADPH, ROS, metabolism, proteasome, KEAP1, MDM2, chemotherapy, BSO, piperlongumine, BPTES, brusatol Received : November 1, 2012, Accepted : November 19, 2012, Published : November 19, 2012 Abstract The transcription factor nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 or NRF2, is a master regulator of the anti-oxidative stress response and positively controls the expression of a battery of anti-oxidative stress response proteins and enzymes implicated in detoxification and glutathione generation. Although its detoxifying activity is important in cancer prevention, it has recently been shown that cancer cells also exploit its protective functions to thrive and resist chemotherapy. NRF2 was also shown to the pentose phosphate pathway and glutaminolysis, which promotes purine synthesis for supporting rapid proliferation and glutathione for providing anti-oxidative stress protection. Evidence obtained from cancer patients and cell lines suggest that NRF2 is highly active in a variety of human cancers and is associated with aggressiveness. p53 is a tumor suppressor that also promotes an anti-oxidative stress metabolic program and glutaminolysis. Here we will discuss the similarities between NRF2 and p53 and review evidence that p53 might be exploited by cancer cells to gain protection against oxidative stress, as is the case for NRF2. We discuss findings of co-regulation between these transcription factors and propose possible therapeutic strategies that can be used for treatment of cancers that harbor WT p53 and express high levels of NRF2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.754

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 109

Metadata

Authors
Rotblat, B., Melino, G., & Knight, R. A.
Venue
Oncotarget
Published
2012-11-19
Volume
3
Issue
11
Pages
1272-1283
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1642779520
Cited by
109
References
47
FWCI
2.90
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NRF2 and p53: Januses in cancer? https://app.cochat.ai/papers/10.18632/oncotarget.754
The paper
Rotblat, B., Melino, G., & Knight, R. A. (2012). NRF2 and p53: Januses in cancer? Oncotarget. https://doi.org/10.18632/oncotarget.754

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.